Source link : https://www.newshealth.biz/health-news/bispecific-antibodies-fare-less-well-in-real-world-analysis/
SAN DIEGO — Compared with clinical trials, a real-world retrospective analysis has linked the bispecific antibodies epcoritamab (Epkinly) and glofitamab (Columvi) to somewhat poorer outcomes in relapsed or refractory large B-cell lymphoma (LBCL). In a presentation here at the American Society of Hematology (ASH) 2024 Annual Meeting, researchers reported that of 172 patients treated with […]
Author : News Health
Publish date : 2024-12-07 21:58:18
Copyright for syndicated content belongs to the linked Source.
inHealth